Ahmad Al Jijakli
Research Subjects
Research Interests
Ahmad Al Jijakli has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Leary
Department of Medical Oncology, Gustave Roussy, Villejuif, France
3 shared publications - Aline Renneville
INSERM U1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France
3 shared publications - Ambroise Marçais
Service d'Hématologie Adulte, Hôpital Necker-Enfants Malades, APHP
3 shared publications - Arnaud Pagès
Department of biostatistics, Gustave Roussy, Villejuif, France
3 shared publications - Bastien Job
Gustave Roussy Institute of Oncology, Villejuif, France
3 shared publications - Celia Salanoubat
16Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
3 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders
Supplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders
Supplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders
- 31 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (11) , 2241-2253
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders
Purpose: PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to expand under the selective pressure of DNA-damaging chemotherapy. However, whether PPM1D mutations promote the development of hematologic malignancies remains unclear. Experimental Design: We characterized the clinical and genomic profiles of 112 PPM1D-mutated patients across the spectrum of myeloid disorders using a combination of bulk and single-cell analyses on diagnostic and longitudinal samples. Results: Among all patients, 78% had a history of primary cancer, with DNMT3A and TP53 being the most frequently comutated genes. In 10 patients with high-grade serous ovarian cancer, longitudinal analysis showed variable dynamics of PPM1D-mutant clones, with 81% of clones expanding during exposure to alkylating agents. Clonal hierarchy estimation revealed that 44% of patients with PPM1D-mutated AML had a PPM1D mutation in the founder clone, with rare TP53 comutations. Both patients with TP53 wild-type and TP53-mutated AML had poor overall survival. Single-cell DNA and surface protein analysis in seven patients confirmed that PPM1D mutations can arise in the founding clone and are associated with the expression of leukemic markers. Conclusions: PPM1D mutations found in clonal hematopoiesis can spontaneously regress after treatment discontinuation; however, they can also be found in the dominant clone in AML/MDS.
- 31 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (11) , 2241-2253
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders
Purpose: PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to expand under the selective pressure of DNA-damaging chemotherapy. However, whether PPM1D mutations promote the development of hematologic malignancies remains unclear. Experimental Design: We characterized the clinical and genomic profiles of 112 PPM1D-mutated patients across the spectrum of myeloid disorders using a combination of bulk and single-cell analyses on diagnostic and longitudinal samples. Results: Among all patients, 78% had a history of primary cancer, with DNMT3A and TP53 being the most frequently comutated genes. In 10 patients with high-grade serous ovarian cancer, longitudinal analysis showed variable dynamics of PPM1D-mutant clones, with 81% of clones expanding during exposure to alkylating agents. Clonal hierarchy estimation revealed that 44% of patients with PPM1D-mutated AML had a PPM1D mutation in the founder clone, with rare TP53 comutations. Both patients with TP53 wild-type and TP53-mutated AML had poor overall survival. Single-cell DNA and surface protein analysis in seven patients confirmed that PPM1D mutations can arise in the founding clone and are associated with the expression of leukemic markers. Conclusions: PPM1D mutations found in clonal hematopoiesis can spontaneously regress after treatment discontinuation; however, they can also be found in the dominant clone in AML/MDS.